Initiator Pharma reduced operating losses in 2024 while advancing pudafensine and IP2018 in ED and FSD, with strong clinical results and increased industry interest. Cash position declined, but equity improved due to share conversions.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.